Literature DB >> 2142557

Specific inhibition of the synthesis of influenza virus late proteins and stimulation of early, M2, and NS2 protein synthesis by 3-deazaadenosine.

A A Fischer1, K Müller, C Scholtissek.   

Abstract

3-Deazaaristeromycin and 3-deazaadenosine (3DA-Ado) both interfere with the methylation of RNA, but only 3DA-Ado is metabolized to the corresponding homocysteine derivative. In contrast to 3-deazaaristeromycin, 3DA-Ado inhibits the synthesis of late influenza A virus proteins in chicken embryo cells (CEC), while it causes an overproduction of early proteins and of the nonstructural proteins NS2 and M2. Only the former effect of 3DA-Ado can be reversed by concomitant addition of adenosine, but not by guanosine. 3DA-Ado acts only early in the infectious cycle and, after removal of the drug, its effect on the yield of infectious virus is reversible. It can be significantly enhanced by homocysteine thiolactone. Except for the M gene, synthesis of viral mRNA is not significantly affected by 3DA-Ado. We conclude that 3DA-Ado acts via its homocysteine derivative by interfering with a specific post-transcriptional modification of viral mRNA and on splicing of specifically the M mRNA. In L-cells influenza viral protein synthesis is comparable to that in CEC in the presence of 3DA-Ado in that there is only little HA and M1 synthesized, and a severe overproduction of NS2 is observed. Under the experimental conditions 3DA-Ado has no inhibiting effect on the replication of other RNA viruses like Newcastle disease virus, Semliki Forest virus, or West Nile virus whose RNA is not methylated, since they do not have a nuclear phase during replication.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2142557     DOI: 10.1016/0042-6822(90)90517-u

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Studies on the regulation of influenza virus RNA replication: a differential inhibition of the synthesis of vRNA segments in shift-up experiments with ts mutants.

Authors:  L V Gubareva; N L Varich; S G Markushin; N V Kaverin
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

2.  Epitranscriptomic Enhancement of Influenza A Virus Gene Expression and Replication.

Authors:  David G Courtney; Edward M Kennedy; Rebekah E Dumm; Hal P Bogerd; Kevin Tsai; Nicholas S Heaton; Bryan R Cullen
Journal:  Cell Host Microbe       Date:  2017-09-13       Impact factor: 21.023

3.  Quantification of Myofascial Taut Bands.

Authors:  Qingshan Chen; Hua-jun Wang; Ralph E Gay; Jeffrey M Thompson; Armando Manduca; Kai-Nan An; Richard E Ehman; Jeffrey R Basford
Journal:  Arch Phys Med Rehabil       Date:  2015-10-14       Impact factor: 3.966

4.  Amino acid replacements leading to temperature-sensitive defects of the NS1 protein of influenza A virus.

Authors:  S Ludwig; U Vogel; C Scholtissek
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

5.  Inhibition of the intracellular transport of influenza viral RNA by actinomycin D.

Authors:  U Vogel; C Scholtissek
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

6.  Failure to obtain drug-resistant variants of influenza virus after treatment with inhibiting doses of 3-deazaadenosine and H7.

Authors:  C Scholtissek; K Müller
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

7.  Posttranscriptional m(6)A Editing of HIV-1 mRNAs Enhances Viral Gene Expression.

Authors:  Edward M Kennedy; Hal P Bogerd; Anand V R Kornepati; Dong Kang; Delta Ghoshal; Joy B Marshall; Brigid C Poling; Kevin Tsai; Nandan S Gokhale; Stacy M Horner; Bryan R Cullen
Journal:  Cell Host Microbe       Date:  2016-04-21       Impact factor: 21.023

Review 8.  The RNA Modification N6-methyladenosine and Its Implications in Human Disease.

Authors:  Pedro J Batista
Journal:  Genomics Proteomics Bioinformatics       Date:  2017-05-19       Impact factor: 7.691

Review 9.  Epitranscriptomic(N6-methyladenosine) Modification of Viral RNA and Virus-Host Interactions.

Authors:  Hasan Imam; Geon-Woo Kim; Aleem Siddiqui
Journal:  Front Cell Infect Microbiol       Date:  2020-11-24       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.